Cited by 503Cystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) ResearchMycobacterium research and diagnosis

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score

Open access
Martínez-García, Miguel Á., de Gracia, Javier, Vendrell Relat, Monserrat, Girón, Rosa-Maria, Máiz Carro, Luis, de la Rosa Carrillo, David, Olveira, Casilda·2014·European Respiratory Journal

Abstract

Bronchiectasis is a multidimensional disease and, therefore, its severity or prognosis cannot be adequately quantified by analysing one single variable. The objective of the present study was to develop a multidimensional score that classifies the severity of bronchiectasis according to its prognosis. This is an observational multicentre study including 819 patients diagnosed with non-cystic fibrosis bronchiectasis using high-resolution computed tomography. 397 subjects were selected at random to construct the score while the remaining 422 were used for its validation. The outcome was 5-year all-cause mortality after radiological diagnosis. A logistic regression analysis was used to select the variables included in the final score. The final seven-point score incorporated five dichotomised variables: forced expiratory volume in 1 s % predicted (F, cut-off 50%, maximum value 2 points); age (A, cut-off 70 years, maximum value 2 points); presence of chronic colonisation by Pseudomonas aeruginosa (C, dichotomic, maximum value 1 point); radiological extension (E, number of lobes affected, cut-off two lobes, maximum value 1 point); and dyspnoea (D, cut-off grade II on the Medical Research Council scale, maximum value 1 point) to construct the FACED score. The validation cohort confirmed the score’s validity. We conclude that this easy-to-use multidimensional grading system proved capable of accurately classifying the severity of bronchiectasis according to its prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00026313

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A high FACED score of 5 to 7 is associated with median survival of approximately 5.5 years in non-cystic fibrosis bronchiectasis.

    “A high FACED score (5–7) has been associated with median survival of approximately 5.5 years.”

    From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [272]

    The Discussion identifies FACED scores of 5–7 as severe, and the Multivariate analysis reports substantially higher five-year mortality in the severe group. The paper does not report a median survival of approximately 5.5 years; its stated follow-up was five years. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • The paper says non-CF bronchiectasis transplant timing is difficult and that FACED and BSI are used to characterize severity and prognosis.

    “Determining transplant timing is difficult due to the wide range of etiologies and demographics. Two non-CF bronchiectasis severity assessment tools were developed from the overall population (not limited to those with advanced lung disease): the FACED score [FEV1, Age, Chronic Pseudomonas aeruginosa, Extension to 1–2 lobes, Dyspnea by modified Medical Research Council scale] and the bronchiectasis severity index (BSI), which adds BMI and exacerbation frequency.”
  • The FACED score and bronchiectasis severity index were developed from the overall non-cystic fibrosis bronchiectasis population, not limited to advanced lung disease.

    “Two non-CF bronchiectasis severity assessment tools were developed from the overall population (not limited to those with advanced lung disease): the FACED score [FEV1, Age, Chronic Pseudomonas aeruginosa, Extension to 1–2 lobes, Dyspnea by modified Medical Research Council scale] and the bronchiectasis severity index (BSI), which adds BMI and exacerbation frequency.(272, 273)”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Martínez-García, M. Á., de Gracia, J., Vendrell Relat, M., Girón, R.-M., Máiz Carro, L., de la Rosa Carrillo, D., & Olveira, C.
Affiliations
Hospital Regional Universitario de Málaga (ES)
Venue
European Respiratory Journal
Published
2013-11-14
Volume
43
Issue
5
Pages
1357-1367
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2154718962
Cited by
503
References
33
Citations by year
2026: 39 · 2025: 27 · 2024: 50 · 2023: 30 · 2022: 47 · 2021: 46 · 2020: 45 · 2019: 36 · 2018: 55 · 2017: 61 · 2016: 31 · 2015: 23 · 2014: 10
FWCI
17.38
Type
journal article
Language
en
Open access
Locations
  • European Respiratory Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
Keywords
non-cystic fibrosis bronchiectasis, FACED score, bronchiectasis severity, prognosis, forced expiratory volume, dyspnea, all-cause mortality, high-resolution computed tomography
MeSH terms
Aged, Bronchiectasis, Female, Follow-Up Studies, Forced Expiratory Volume, Humans, Male, Middle Aged, Predictive Value of Tests, Prognosis, Regression Analysis, Severity of Illness Index, Tomography, X-Ray Computed, Pulmonary Medicine, Cohort Studies, Treatment Outcome, Area Under Curve, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review